Zevra Therapeutics (NASDAQ:ZVRA) Upgraded at Wall Street Zen
Wall Street Zen upgraded shares of Zevra Therapeutics (NASDAQ:ZVRA – Free Report) from a hold rating to a buy rating in a research report report published on Thursday. ZVRA has been the subject of several other reports. Cantor Fitzgerald restated an “overweight” rating and set a $25.00 price objective on shares of Zevra Therapeutics in […]
Wall Street Zen upgraded shares of Zevra Therapeutics (NASDAQ:ZVRA – Free Report) from a hold rating to a buy rating in a research report report published on Thursday. ZVRA has been the subject of several other reports. Cantor Fitzgerald restated an “overweight” rating and set a $25.00 price objective on shares of Zevra Therapeutics in […]
